Large granular lymphocytosis during dasatinib therapy

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Dasatinib, a tyrosine kinase inhibitor (TKI), treats imatinib-resistant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL).
• Large granular lymphocytes (LGLs) are immune cells that can proliferate, leading to LGL lymphocytosis, often involving cytotoxic T cells or NK cells.
• An expansion of LGLs is observed in some CML and Ph(+) ALL patients during dasatinib treatment, sometimes associated with symptoms like fever, colitis, and pleural effusions.

Purpose of the Study:

• To investigate the role of LGLs in patients treated with dasatinib.
• To analyze the morphologic, phenotypic, clinical, and functional characteristics of LGL subsets that expand during dasatinib therapy.

Main Methods:

• Morphologic analysis of LGLs.
• Phenotypic characterization of LGL subsets.
• Clinical data review of patients.
• Functional assessment of amplified LGLs in vivo.

Main Results:

• LGL clonal expansion during dasatinib therapy is associated with excellent and durable responses in CML and Ph(+) ALL patients.
• LGL lymphocytosis may indicate an aberrant immune response, potentially contributing to the elimination of residual leukemic cells.
• The study characterized the specific features of LGL subsets amplified during dasatinib treatment.

Conclusions:

• LGL expansion during dasatinib therapy is a notable phenomenon in leukemia treatment.
• Amplified LGLs appear to play a role in the efficacy of dasatinib, correlating with positive patient outcomes.
• Further research into LGLs could offer insights into novel therapeutic strategies for CML and Ph(+) ALL.